Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of late-stage disruptive clinical products. Accentia has a portfolio of currently marketed respiratory products and a pipeline of products in clinical development. The company''s lead respiratory product candidate is SinuNase, which is under clinical development to treat chronic sinusitis. SinuNase is a novel application and formulation of a known anti-fungal exclusively licensed from the Mayo Foundation for Medical Education and Research. The product has been Fast Tracked by the FDA and the Company has commenced a Phase three clinical trial. The Company''s other lead product is BiovaxID, a patient-specific anti-cancer vaccine for the treatment of follicular non-Hodgkin''s lymphoma. BiovaxID, which is being developed by Accentia''s subsidiary Biovest International, Inc.